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Abstract: Human SARS coronavirus 2 (SARS-CoV-2) causes the current global COVID-19 pandemic. The production of an efficient
vaccine against COVID-19 is under heavy investigation. In this study, we have designed a novel multiepitope DNA vaccine against
SARS-CoV-2 using reverse vaccinology and DNA vaccine approaches. Applying these strategies led to reduce the time and costs of
vaccine development and also improve the immune protective characteristics of the vaccine. For this purpose, epitopes of nucleocapsid,
membrane glycoprotein, and ORF8 proteins of SARS-CoV-2 chose as targets for B and T-cell receptors. Accordingly, DNA sequences
of selected epitopes have optimized for protein expression in the eukaryotic system. To this end, the Kozak and tissue plasminogen
activator sequences were added into the epitope sequences for proper protein expression and secretion, respectively. Furthermore,
interleukin-2 and beta-defensin 1 preproprotein sequences were incorporated to the designed DNA vaccine as an adjuvant. Modeling
and refinement of fused protein composed of SARS-CoV-2 multiepitope antigens (fuspMA) have performed based on homology
modeling of orthologous peptides, then constructed 3D model of fuspMA was more investigated during 50 ns of molecular dynamics
simulation. Further bioinformatics predictions demonstrated that fuspMA is a stable protein with acceptable antigenic features and
no allergenicity or toxicity characteristics. Finally, the affinity of fuspMA to the MHC I and II and TLRs molecules validated by the
molecular docking procedure. In conclusion, it seems the designed multiepitope DNA vaccine could have a chance to be introduced as
an efficient vaccine against COVID-19 after more in vivo evaluations.
Key words: DNA vaccine, reverse vaccinology, immunoinformatic, COVID-19, SARS-CoV-2

Abbreviations: Severe acute respiratory syndrome
coronavirus 2: SARS-CoV-2, tissue plasminogen activator:
TPA, fused protein composed of SARS-CoV-2 Multiepitope
Antigens: fuspMA of SARS-CoV-2, reverse vaccinology:
RV vaccinology, molecular dynamic simulation: MD
simulation, root mean square deviation: RMSD, root mean
square fluctuation: RMSF, radius of gyration; RG.
1. Introduction
The novel human severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that causes coronavirus
disease 2019 (COVID-19) is a positive-sense singlestranded RNA (+SS-RNA) virus (Park, 2020; Velavan and
Meyer, 2020). SARS-CoV-2 belonged to the Coronaviridae
family and genus of Betacoronavirus (Helmy et al., 2020).
COVID-19 was first observed as a respiratory syndrome
disease at the end of 2019 in Wuhan city of China and is
responsible for significant mortality and morbidity in the
human population in the current worldwide pandemic

(Wu et al., 2020). Previously, various outbreaks of infections
caused by bacteria, viruses, and other pathogens have
been reported. In a recent one, the previous outbreak of
the SARS coronavirus in 2002–2004 caused several deaths
(Ksiazek et al., 2003; Anderson et al., 2004). Nowadays,
COVID-19 spread around the world and became a crucial
health problem with various mutations leading to create
different variants of viruses such as Deltacoronavirus,
Alphacoronavirus, Gammacoronavirus and the case which
recently spread along the globe, Omicron coronavirus (Wu
et al., 2020; Salcedo et al., 2022).
Efficient vaccination is the most relevant approach
to prevent the contagion of an infection and subsequent
challenges. Various procedures have been developed for
vaccine design and production since attenuated-infectious
agents until the novel DNA vaccines. The development
of multiepitope DNA vaccines by using the reverse
vaccinology (RV) approach is a novel and innovative
strategy for vaccine production (Li and Petrovsky, 2016;
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Enayatkhani et al., 2020). The RV approach was first
invented by Rappouli for the B serotype of Neisseria
meningococcus and after that, it has been used in a variety
of vaccine design projects (Rappuoli, 2001; Rappuoli et
al., 2016). Currently, improvement in immunoinformatic
by simulation and prediction of B and T-cell epitopes in
available data banks have contributed to the development
of DNA vaccines based on the RV method (Dhanda
et al., 2019). Today, this method has been attended by
researchers because of its advantages like requiring short
time for design and production of the candidate vaccine
and induction of an adequate immune protective result.
Despite the traditional vaccine development methods,
designing a DNA vaccine based on the RV approach has
noticeable advantages. To produce a multiepitope-based
vaccine in its peptide form, the DNA sequence of the
related protein should be synthesized, be expressed in
conventional hosts, and finally expressed antigens should
be purified and prepared for delivery to individuals.
Therefore, peptide-based vaccine development and
production could be expensive and time-consuming on a
large scale because of indicated steps. Despite of peptidebased vaccines, DNA vaccines as a new generation of
vaccines containing just a DNA sequence of some selected
antigens to induce immunity against the indicated
pathogen. Using DNA vaccines could reduce costs and
time for the vaccine invention and production processes
simultaneously, while it has also its challenges (Heppell
and Davis, 2000). Nevertheless, there are different reports
about the design and production of DNA vaccines, to our
acknowledge, none of them were approved for human
beings until the covid-19 pandemic appearance (Silveira

et al., 2021). In the current work, we have designed a DNA
vaccine by combining the sequences of the most potent
epitopes of SARS-CoV-2. This kind of designed DNA
vaccine can reduce the time and costs of the prepared
vaccine in comparison to similar peptide-based vaccines.
This strategy could increase the number of the presented
antigens to immune cells in comparison to one-epitope
DNA vaccines. According to the importance of surface
proteins that could induce a strong and effective immune
response, the nucleocapsid protein and membrane
glycoprotein were selected for epitope prediction (Figure
1). Furthermore, the ORF8 protein with a high rate of
antigenicity was selected for vaccine designing (Figure
1) (Kumar et al., 2013). To enhance the immunogenicity
of the proposed vaccine, protein adjuvants were added
to the designed peptide sequence. For this reason, the
amino acid sequence of beta-defensin 1 preproprotein and
interleukin-2 added into the proposed vaccine sequence
(Barouch et al., 2004). Moreover, to design an effective
DNA vaccine some features such as necessary elements for
gene expression and protein production, proper vectors
and promoters, and suitable delivery systems must be
considered to achieve an appropriate vaccine (Manam et
al., 2000). To this aim, the Kozak sequence was used in the
initial part of the nucleic sequence of predicted epitopes and
sequence of tissue plasminogen activator (TPA) was used
as a signal peptide element (Garmory et al., 2003). The TPA
sequence acts as a signal peptide that causes to secrete the
desired protein into the extracellular environment of the
eukaryotic aimed cells. This process could lead to a more
proper exposition of the proposed sequence of vaccines
within the immune system to make an effective immune

Figure 1. (A) Schematic presentation of structure of SARS-CoV-2. (B) Sequences of genes in genome of SARS-CoV-2 (Mohammad
et al., 2020). In current project, epitopes from the nucleocapsid proteins, membrane glycoprotein, and ORF8 protein selected and
evaluated for deigning an efficient DNA vaccine.
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response. The final chimeric-designed DNA sequence can
clone in a suitable vector for further investigations. In the
end, the cloning of the final sequence containing the Kozak
sequence, TPA, TEV protease cleavage site into the DNA
expression pVax1 vector simulated by SnapGene software
(Xu et al., 2017).
2. Materials and methods
2.1. Primary data collection
The first step of this study began by retrieving related
protein sequences of human SARS coronavirus 2.
Therefore, sequences of structural proteins of the
human coronavirus 2 were obtained in FASTA format
from the NCBI database. In a similar way, interleukin-2
(GenBank: AAB46883.1) and beta-defensin 1 preproprotein
(NP_005209.1) sequences retrieved in FASTA format from
NCBI database (https://www.ncbi.nlm.nih.gov/). Also, the
three-dimensional structure and amino acid sequence of
human TLR3, TLR4, MHC I, and MHC II in PDB format
were obtained from protein data bank (https://www.rcsb.
org/) (Berman et al., 2007).
2.2. Choosing targeted proteins for designing chimeric
DNA vaccine
After primary analysis, the nucleocapsid protein
(GenBank: QHO62110.1), membrane glycoprotein
(GenBank: QHR84452.1), and ORF8 protein (GenBank:
QHW06065.1) were selected as target proteins. For
this goal, the antigenicity level of considered proteins
was evaluated by using the Vaxijen 2.0 server (http://
www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.
html ) (Doytchinova and Flower, 2007). In continue, the
allergenicity and toxicity of the selected proteins were
studied by AllerTOP v. 2.0 (https://www.ddg-pharmfac.
net/AllerTOP) (Dimitrov et al., 2014) and Toxin Pred
server (https://webs.iiitd.edu.in/raghava/toxinpred/algo.
php) (Gupta et al., 2013), respectively.
2.3. Epitope prediction of targeted proteins
The immune epitope database (IEDB), which is available
on https://www.iedb.org/, is an applicable tool for epitope
prediction (Vita et al., 2019). This server contains various
tools that are used widely in immunoinformatics studies.
In this study, we used this server to predict B and T-cell
epitopes. The linear B-cell epitopes have been predicted
using available methods and also the MHC I and II
related epitopes have been predicted by the T-cell epitope
prediction tool of the server. Furthermore, all alleles for
MHC I and II molecules were considered in the epitope
prediction process to achieve a universal vaccine.
2.4. Choosing epitopes with high antigenicity, low
allergenicity, and low toxicity to construct a multiepitope
DNA vaccine
To design an appropriate vaccine, antigenicity and
allergenicity of the selected epitopes are so crucial. High
antigenicity levels and lack of allergenicity properties

of an epitope could lead to a stronger immune reaction
and reduction of allergenic responses (Reese et al., 2007).
According to the importance of this point, the epitopes
with higher antigenic features and nonallergen ones
were chosen from the predicted epitopes. Moreover, for
T-cell epitopes selection, epitopes that covered most of
HLA alleles were considered. Also, due the fact that some
amino acid orders in peptide sequences may cause a toxic
function, the toxicity of the selected epitopes sequences
was predicted using the Toxin Pred server as mentioned
above (Gupta et al., 2013).
2.5. Design the amino acid sequence of aimed vaccine
Finally, sequences of selected epitopes should be
attached together to make a united peptide sequence
that was named fused protein composed of SARS-CoV-2
multiepitope antigens (fuspMA of SARS-CoV-2). To this
aim, AAY linkers were used to connect the amino acid
sequence of selected epitopes. In the next step, to increase
the probability of exposing the immune system and take a
stronger immune reaction against the candidate vaccine,
a sequence of protein adjuvants was added to the peptide
sequence. For this, the amino acid sequence of betadefensin 1 preproprotein added into the N terminal and
interleukin-2 sequence added into the C-terminal of the
proposed vaccine sequence using EAAAK linkers.
2.6. Determination of physicochemical properties and
stability of the designed protein
In this section of the study, the physicochemical properties
of the fuspMA of SARS-CoV-2 protein such as half-life,
the amino acid compositions, the isoelectric pH (pI), and
the native charge in pH 7 were analyzed by using related
servers. Innovagen, PepCalc.com–Peptide property
calculator (https://pepcalc.com/) and Protparam (http://
web.expasy.org/cgi-bin/protparam/) servers (Gasteiger
et al., 2005) were used for this aim. In the following, for
prediction of protein disorder as a function of redox state
and potential of protein binding of fuspMA of SARSCoV-2, IUPred 2a (https://iupred2a.elte.hu/) server was
applied (Mészáros et al., 2018). IUPred2A server reported
the results in a graph with a threshold of the area under the
curve (AUC) values that can range from 0.5 for random
predictions to 1 for perfect predictions (Mészáros et al.,
2018).
2.7. Prediction of secondary and 3D structure of
fuspMA of SARS-CoV-2
The structure of a protein is an important issue for its
expression, function, and stability. In this step, we predicted
the secondary structure of our suggested protein using the
Gor IV method of the Prabi server which is accessible on
(https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat/) (Sapay et
al., 2006). In the next step, the 3D structure of the candidate
protein is predicted using the I-TASSER (as ‘ZhangServer’) server (Yang et al., 2015). This server is accessible
at https://zhanglab.ccmb.med.umich.edu/I-TASSER/.
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2.8. Structure refinement of 3D constructed model of
fuspMA of SARS-CoV-2
The protein refining process was performed using
GalaxyWeb server which accessible on (http://galaxy.
seoklab.org/) (HeeShin, 2014) to reduce structural
mistakes in the predicted 3D structure of the protein.
Also, the quality of the refined model of fuspMA of SARSCoV-2 was studied using the PROCHECK server (https://
servicesn.mbi.ucla.edu/PROCHECK/) (Laskowski et al.,
1996).
2.9. Molecular dynamics refinement of corrected
structural model of fuspMA of SARS-CoV-2
The newly created model of the designed protein was
introduced to the molecular dynamics (MD) simulation
to obtain an optimized model and to improve our
understanding of its physicochemical properties in detail.
Simulations and analyses of produced trajectories of
fuspMA of SARS-CoV-2 were performed using Gromacs
(version 4.5.5) software package (Van Der Spoel et al.,
2005). Created topologies of designed protein by I-TASSER
server were defined using OPLS-AA force field. The
coordinates were placed in separate cubic boxes, solvated by
the SPC216 model for the water molecule, and neutralized
by the addition of a sufficient number of ions. After all of
the indicated steps, the solvated and neutralized structures
were minimized by the steepest descent minimization
algorithm until the maximum force <1000.0 kJ/mol/nm
was reached. The structure was subjected to 100 ps of MD
simulations in the canonical (NVT) ensemble to increase
the temperature of the systems to 298 K. After 200 ps of
NPT-MD equilibration, the final equilibrated structures
were used to carry out 50 ns MD simulations. During the
simulations, only hydrogen bonds within a distance cutoff
of 0.35 nm between the cooperated donor and acceptor
with a donor-hydrogen-acceptor angle cutoff of 30° were
taken into account.
The particle-mesh Ewald algorithm was used to account
for long-range electrostatic interactions (Simmonett et
al., 2014). The 50 ns NPT-MD simulation process was
performed three times and all of the related represented
data is the average value of indicated three times repeated
simulations. For visualization of protein structures, we
used VMD (Humphrey et al., 1996), UCSF Chimera
programs (Pettersen et al., 2004), and ENDscript 2 serverbased tools (Robert and Gouet, 2014).
2.10. Investigation of interaction of fuspMA of SARSCoV-2 with human MHC I, MHC II, TLR3, and TLR4 by
protein-protein docking approach
Interactions of fuspMA of SARS-CoV-2 with human MHC
I, MHC II, TLR3, and TLR4 were investigated by proteinprotein docking procedure. Molecular docking study was
performed using the ClusPro server in antibody-mode
(https://cluspro.org/help.php) (Kozakov et al., 2017) to
predict and measurement of the affinity of fuspMA of
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SARS-CoV-2 structure after 50 ns MD simulation as a
ligand to TLR3 (3ULS.pdb) (Luo et al., 2012), TLR4 (4R7N.
pdb) (Loyau et al., 2015), MHC I (4UQ3.pdb) (Choo et
al., 2014) and MHC II (4GBX.pdb) (Pos et al., 2012) as a
receptor (Vajda et al., 2017). The energy of binding for the
docked complexes as weighted score was calculated based
on the below equation by Cluspro server;

EEnergy of binding = 0.50Erep + −0.20Eatt + 600Eelec + 0.25EDARS
(Kozakov et al., 2017).

2.11. Construction of optimized nucleotide sequence for
the designed DNA vaccine
As noticed before, to designing an efficient DNA vaccine,
we designed the nucleotide sequence based on the system
of the eukaryotic cells. For this purpose, the amino acid
sequence of the suggested vaccine was backtranslated into
nucleotide sequences based on eukaryotic codon usage
using the Jcat server (http://www.jcat.de/) (Grote et al.,
2005). Furthermore, signal peptide and Kozak sequence
were added into the initial of the DNA sequence to
optimize the transcription and gene expression. To this
aim, the nucleic sequence of tissue plasminogen activator
(TPA) (GenBank: E02360) was obtained from the NCBI
database. Furthermore, to make a cleavage between the
vaccine sequence and TPA after the expression process, a
protease cleavage site has located between the TPA signal
peptide and fuspMA. Finally, the constructed sequence
has been cloned into a pVax1 eukaryotic vector to use for
in vitro expression. After confirming suitable expression
of fuspMA of SARS-CoV-2 in eukaryotic cells in cell
culture conditions, it could be applied for the in vivo
immunization tests.
3. Results
3.1. Epitope prediction, selection, and estimation of
antigenicity, allergenicity, and toxicity of chosen epitopes
To design a multiepitope vaccine, the nucleocapsid protein,
membrane glycoprotein, and ORF8 protein were selected
from SARS-CoV-2 virus proteins using the NCBI database
as indicated above (Figure 1). In the following, each protein
sequence is used for B and T-cell epitope prediction using
the IEDB server (Vita et al., 2019). The resulted epitopes
and their antigenicity, allergenicity, and toxicity are shown
in Table 1. Finally, 3 linear B-cell epitopes and 10 T-cell
related epitopes were chosen and considered as a vaccine
candidate. To construct an effective vaccine, it is necessary
to consider three main factors containing; antigenicity
level, allergenicity, and toxicity of the proposed amino acid
sequence of the vaccine. Accordingly, the selected epitopes
studied for these aims and obtained results confirmed
the selected ones have shown appropriate antigenic
features and lack of allergenic and toxic properties (Table
1). Between the selected epitopes, “DPNFKD” from
nucleocapsid protein and “IQYIDIGNY” from ORF 8 have
the highest predicted antigenicity (Table 1).

NEMATI et al. / Turk J Biol
Table 1. Selected epitopes and their estimated antigenicity, allergenicity, and toxicity features for the
designed multiepitope DNA vaccine against SARS-CoV-2.
Epitope
DPNFKD
RRGPEQTQGNFGDQELIRQGTDYK
RNSTPGSSRGTSPAR
PEQTQGNFGDQELIR
KTFPPTEPKK
LVIGAVILR
SELVIGAVI
DEAGSKSPIQYIDIGN
YIDIGNYTV
IQYIDIGNY
QYIDIGNYTV
DEAGSKSPIQYIDIG
TQHQPYVVDDPCPIH

Related protein
Nucleocapsid protein
Nucleocapsid protein
Nucleocapsid protein
Nucleocapsid protein
Nucleocapsid protein
Membrane glycoprotein
Membrane glycoprotein
ORF 8
ORF 8
ORF 8
ORF 8
ORF 8
ORF8

3.2. Construction of a peptide sequence containing
sequences of selected antigens and adjuvants
After selecting of proper epitopes, the primary peptide
sequence of the vaccine was designed using linkers and
adjuvant sequences. The beta-defensin 1 preproprotein
and interleukin-2 were used as adjuvants that connected to
epitope sequences by EAAAK linkers. Also, AAY linkers
are used to attach the selected epitopes to each other to
construct a unique peptide named fuspMA. The amino
acid sequence of fuspMA is depicted in Figure 2A.
3.3. Physicochemical properties of fuspMA of SARSCoV-2 as vaccine candidate
As mentioned before, the physicochemical properties
of the protein sequence after designing were studied.
The obtained results showed, the constructed protein
(fuspMA) consists of 382 amino acids with a molecular
weight of 42527.46 g/mol. The isoelectric pH and the net
charge at pH 7 were predicted at about 5.99 and –4.1,
respectively. In the following, the half-life of the protein
base on its sequence is estimated about 30 h in mammalian
reticulocytes for the in vivo condition. Protein disorder
state and possibility of binding of fuspMA to other peptide
structures for fuspMA of SARS-CoV-2 that introduces as
a vaccine candidate was predicted by Iupred 2.0 designed
graph. The designed graph is illustrated in Figure 3. Based
on obtained results, the sequence of fuspMA of SARSCoV-2 has not a great chance to act as an anchor for
binding to the registered structures in IUPred2A server
(Figure 3).
3.4. Prediction of Secondary and 3D structure of fuspMA
of SARS-CoV-2
The secondary and 3D structure of fuspMA of SARSCoV-2 was predicted using I-TASSER server based on

Antigenicity
2.84
0.62
0.75
0.63
0.76
1.10
0.64
0.911
1.3
2.09
1.49
1.02
0.67

Allergenicity
No
No
No
No
No
No
No
No
No
No
No
No
No

Toxicity
No
No
No
No
No
No
No
No
No
No
No
No
No

the amino acid sequence of the constructed protein and
homology modeling of orthologous proteins (Zhang,
2008) and refined by the GalaxyWeb server (Ko et al.,
2012) (Figure 2). According to the obtained results, model
number 1 with the clash score of 30.5 and RMSD of 0.505
A˚ was the most favorable one (Table 2). The created
and refined 3D model of fuspMA by I-TASSER server
were minimized and then were simulated. To extend our
understanding of fuspMA of SARS-CoV-2, the created
3D model of fuspMA was investigated during 50 ns of
MD simulation (Figure 4). As indicated in Figure 4A that
depicts root mean square deviation (RMSD) graph of Cα
of fuspMA during simulation time, fuspMA of SARSCoV-2 was reached to its stable conformation after near
10 ns of simulation process and the average of RMSD
for the Cα of fuspMA during 50 ns of MD simulation
is 0.93951 nm in comparison with the minimized
generated structure of fuspMA of SARS-CoV-2 (Figure
4A). Calculated root mean square fluctuations (RMSF)
of Cα of residues of fuspMA during 50 ns of simulation
process were in ordinary ranges for a stable protein during
simulation time (Figure 4B). Furthermore, the average of
radius of gyration for fuspMA of SARS-CoV-2 during 50
ns of MD simulation was calculated as 2.2974 nm (Figure
4C). As could be seen in the graph of the radius of gyration
for fuspMA of SARS-CoV-2 (Figure 4C), this index did
not fluctuate significantly during simulation time that
shows the overall structure and the shape of fuspMA of
SARS-CoV-2 after reaching to its stable structure was not
changed a lot during the simulation process. To investigate
the behavior of fuspMA of SARS-CoV-2 during simulation
time, secondary and 3D simulated structures were studied

267

NEMATI et al. / Turk J Biol

Figure 2. Amino acid sequence, secondary structure (A), and 3D structure (B) of the generated model of fused
protein composed of SARS-CoV-2 multiepitope antigens (fusMA of SARS-CoV-2) that created by I-TASSER server
based on homology modeling and refined by GalaxyWeb server to reduce structural mistakes in the predicted
3D topologies. fusMA of SARS-CoV-2 is mainly composed of sequences of most potent linear antigens of SRASCoV-2, sequences of beta-defensin 1 preproprotein and interleukin-2 as adjuvants, and EAAAK and AAY as linkers.

Figure 3. The stability plot of fused protein composed of SARS-CoV-2 multiepitope antigens (fuspMA of SARS-CoV-2)
disorders that are drawn by Iupred2a server. Presented data show disordered protein regions using IUPred2 and disordered
binding regions using ANCHOR2 of the fuspMA of SARS-CoV-2 refined structure.

every 10 ns (Figure 5). As could be seen in Figure 5 and
indicated above, after 10 ns of MD simulation fuspMA
of SARS-CoV-2 reached to its stable form, and reported
fluctuations could be seen just in the random coil regions
of the protein (Figures 4B and 5).
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3.5. Molecular docking study of interaction of fuspMA
of SARS-CoV-2 to immunological response involving
receptors
The molecular docking process was performed using
the Cluspro 2.0 protein-protein docking server (https://

NEMATI et al. / Turk J Biol
Table 2. Results of the refinement process of 3D structure of fuspMA that created by I-TASSER
server based on homology modeling of orthologous proteins. The GalaxyWeb server suggested
5 models which ordered based on the 3D refine score.
MODEL

GDT-HA RMSD MOLPROBITY

CLASH POOR
RAMA
SCORE PARAMETERS FAVORED

INITIAL

1.0000

191.4

0.000

4.248

8.6

74.5

MODEL 1

0.9169

0.505

2.834

30.5

1.2

75.0

MODEL 2

0.9123

0.511

2.748

29.5

0.9

75.0

MODEL 3

0.9175

0.502

2.731

27.7

0.6

74.2

MODEL 4

0.9130

0.518

2.826

30.1

1.2

75.3

MODEL 5

0.9188

0.493

2.805

28.8

1.2

75.5

Figure 4. (A) Average of root mean square deviation (RMSD)
of Cα of fused protein composed of SARS-CoV-2 multiepitope
antigens (fuspMA of SARS-CoV-2). While average of RMSD for
fuspMA of SARS-CoV-2 is 0.9395 nm during 50 ns of molecular
dynamic simulation, this value is 0.7248 during first 10 ns and
0.9932 for 10 to 50 ns of simulation process. At the 50 ns of MD
simulation, RMSD of fuspMA of SARS-CoV-2 was reached to
1.0632 nm in comparison to the original refined 3D model of
fuspMA of SARS-CoV-2 that was simulated. (B) Root mean
square fluctuations (RMSF) of Cα of residues of fuspMA, (C) and
radius of gyration of fuspMA of SARS-CoV-2 (C) during 3 times
of 50 ns of molecular dynamic simulation.

cluspro.org/help.php) (Vajda et al., 2017) to ensure
interactions between receptor molecules containing
TLR3, TLR4, MHC I and MHC II and the refined and
simulated model of fuspMA as a ligand. The molecular
docking process was performed in antibody-mode for
each receptor. Docking scores in antibody mode included
the center lowest energy of –305.8, –313.9, –452.6, and
–381.2 for human MHC I, MHC II, TLR 3, and TLR 4,
respectively (Figure 6).
3.6. Sequence engineering for designing multiepitope
DNA vaccine against COVID-19
To design an effective DNA vaccine some more structural
elements should be considered. Firstly, the amino acid
sequence of selected epitopes should be backtranslated into
a nucleic sequence based on the codon usage algorithm of
the target organism. Secondly, signal peptide and Kozak
sequence should be added to the first of the nucleic
sequence. The graphical view of the final construct of our
designed DNA vaccine in order from the N-terminal to
C-terminal is illustrated in Figure 7. The final sequence
consisted of a Kozak consensus sequence, tissue
plasminogen activator (TPA) signal peptide, TEV protease
cleavage site, and the vaccine sequence (supplementary
1). In addition, accommodation of the final construct of
the proposed multiepitopes DNA-vaccine in pVax1 as
eukaryotic expressing vector was demonstrated in Figure
8.
4. Discussion
4.1. Construction of a chimeric peptide to use for
vaccination against COVID-19
Various pathogens cause different diseases in the world and
some of them became major health problems for human
life. Several outbreaks of viral and bacterial infections
were observed previously such as the Q fever outbreak in
the Netherlands in 2007, outbreaks of H5N1 influenza in
2003–2004, severe acute respiratory syndrome (SARS) in
2003–2004, and the current global pandemic of the SARS-
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Figure 5. Snapshot of secondary structure and 3D structure of fused protein composed of
SARS-CoV-2 multiepitope antigens (fuspMA of SARS-CoV-2) at the beginning of molecular
dynamic simulation (A), after 10 ns molecular dynamic simulation (B), after 20 ns molecular
dynamic simulation (C), after 30 ns molecular dynamic simulation (D), after 40 ns molecular
dynamic simulation (E), after 50 ns molecular dynamic simulation (F).

CoV-2 (Zhong et al., 2003; Mase et al., 2005; Karagiannis
et al., 2007; Wu et al., 2020).
As mentioned before, the RV method was first used
for the development of an effective vaccine against
Meningococcus bacteria as the causative agent of bacterial
meningitis that had no efficacious vaccine before that time
(Rappuoli, 2000). This approach was reported notably
for various pathogens, so several databases have been
created for this object (Rappuoli, 2001). In this strategy
of vaccine development, antigenic epitopes of proteins
that can stimulate the immune system were selected for
further considerations. In the following, chosen epitopes
were ordered in an amino acid sequence and connected
by linkers. Then, the protein sequence is converted to the
DNA sequence that could be synthesized and cloned into
suitable vector. Finally, protein expression and purification
should be performed to achieve a purified protein to
use for animal modeling studies (He et al., 2010). This
approach was previously applied for various pathogens and
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reported in lots of papers (Rappuoli, 2000). For instance,
M. Oprea and F. Antohe applied the T-cell epitope as a
suggested vaccine against Staphylococcus aureus. They
selected 9-mer immunogen epitopes of surface-exposed
proteins using web databases (Oprea and Antohe, 2013).
Furthermore, L. John et al. utilized the RV approach to find
vaccine candidates against highly pathogenic species of
Leishmania major and Leishmania infantum. They selected
transmembrane proteins from the total proteome of the
targets and considered them for further investigations.
Finally, they reported 19 epitopes for their recommended
vaccine against Leishmania (John et al., 2012). In a recent
project, during the current pandemic of the human
SARS coronavirus 2, M. Enayatkhani and his colleagues
have studied in silico design of a novel multiepitope
vaccine against the COVID-19 infection using the reverse
vaccinology approach (Enayatkhani et al., 2020). In that
project, they have selected the nucleocapsid, ORF3a, and
membrane protein as target proteins to examine their
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Figure 6. Protein-protein docking of fused protein composed of SARSCoV-2 multiepitope antigens (fuspMA of SARS-CoV-2) (orange
red) against human MHC I (purple) (A), MHC II (purple) (B), TLR
3 (purple) (C) and TLR 4 (purple) (D). Weighted scores of docked
molecules as center and lowest energies are also reported here.

Figure 7. Graphical shape of sequence of the designed multiepitope DNA vaccine
against SARS-CoV-2.

potential of immunogenicity as B and T-cell epitopes
(Enayatkhani et al., 2020). DNA vaccines or plasmidbased vaccines are the other generations of vaccines which
were first introduced in 1990. This strategy performs by
inducing protein expression upon direct intramuscular
injection of plasmid DNA in myocytes (Wolff et al.,

1990). These vaccines are a new type of subunit vaccines
that allow protein expression in mammalian cells after
introduction of plasmid or recombinant viral vectors
encoding the selected protective antigens (Ivory and
Chadee, 2004). The innate immunity can be activated by
recognition of the double-stranded DNA of the plasmid
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Figure 8. Schematic structure of the designed DNA-vaccine that cloned in pVax1
eukaryotic vector.

backbone, while adaptive responses are activated by
antigen proteins which were cloned into the vector by
involving MHC I or MHC II from CD8+ and CD4+ T
cells. Therefore, DNA vaccines can stimulate innate and
adaptive immune responses, simultaneously (Ghanem
et al., 2013). Due to the global pandemic of COVID-19
disease, efficient DNA vaccines could be approved
because of a series of advantages, including the ease of
production, safety, simple administration, and genetic
stability. Currently, many researchers heavily investigate
the design and production of proper DNA vaccines for
COVID-19. Trevor R. F. Smith and his research group
have designed a DNA vaccine against SARS coronavirus
2. For this purpose, they have selected spike protein as the
major surface antigen of coronaviruses and introduced
INO-4800 as a potential COVID-19 vaccine candidate
(Smith et al., 2020). Today, ZyCoV-D as a DNA plasmidbased COVID-19 vaccine encoding SARA-CoV-2 spikeprotein that is developed by Indian pharmaceutical
company is approved in India (Dey et al., 2021). Although
the DNA vaccination approach could be a cost-effective
and fast method for vaccination in massive populations
against pathogens, lacking a proper delivery system is
still the main problem. To overcome this challenge, Shah
and his colleagues have shown that using nanoparticles
can be considered a convenient delivery system that is
also able to increase the stability of the vaccine (Shah et
al., 2014). Based on our previous knowledge about DNA
vaccines, most of the DNA vaccines contain almost one
gene that encodes a particular antigen protein (Suhrbier,
1997; Smith et al., 2020). In the current study, we apply a
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novel strategy to design a new DNA vaccine that contains
multiple epitopes from the SARS-CoV-2 virus. Here, we
have combined the strategies of the RV and DNA vaccine
designing processes to achieve a cost-effective, fast, and
protective vaccine against the causal agent for the current
COVID-19 pandemic. In addition to the above points,
designing a vaccine based on different protein antigens
could lead to increase the reliability of the vaccine
against various mutations that cause proper immunity
versus different variants of the virus between vaccinated
communities. Many of existed vaccines are not induced
reliable immunity against the newly spread variants
of SARS-CoV-2 such Omicron coronavirus and this
phenomenon leads to emerging another wave of pandemic
just after general community vaccination. To this aim, we
designed a multiepitope DNA vaccine encoding epitopes
of the nucleocapsid, membrane glycoprotein, and ORF8
proteins of the SARS-CoV 2 virus that are optimized for
expression in mammalian cells in order to overcome the
mutations and make a proper vaccine against this virus
(Figures 7 and 8). We have considered and used both B
and T-cell epitopes for our designed DNA vaccine that
was previously considered and recommended (Florindo et
al., 2020). We investigated the expressed chimeric protein
(fuspMA of SARS-CoV-2) by the constructed DNA
vaccine and showed fuspMA is a stable peptide and has
a suitable half-life in the eukaryotic cells, simultaneously.
Furthermore, the antigenicity of the encoded peptide
sequence was studied by Vaxijen 2.0 server (Doytchinova
and Flower, 2007) and considered a probable antigen
with a score of 0.93. In the following, other features of the
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encoded protein, including physicochemical properties,
secondary and 3D structure, amino acid compositions,
and geometric features have been predicted using online
databases and molecular dynamics simulation approaches.
4.2. Evaluation of possible induction of an effective
immune response by fusMA of SARS-CoV-2 through its
interaction with immune system receptors
Finally, the molecular docking study of the encoded
protein (fusMA of SARS-CoV-2) with MHC I and II
classes, and TLR3 and 4 molecules was performed and
obtained results confirmed the potential of fuspMA as
an efficient immunogenic vaccine. Nonclassical major
histocompatibility class I (HLA class I histocompatibility
antigen) molecule in complex with B2M/beta-2microglobulin involved in immune self-nonself
discrimination (Llano et al., 1998). Peptide-bound HLAE-B2M heterotrimeric complex primarily functions as
a ligand for natural killer (NK) cell inhibitory receptor
KLRD1-KLRC1 (Braud et al., 1998) and through
interaction with
CD8+ cytotoxic T cells, ultimately
triggering antimicrobial immune responses consist of
secretion of type 1 cytokines (IL-1, IL-8, TNF-alpha, and
IFN-gamma), cell-mediated immunity, IgG1, and IgG3
secretion, and inflammation response that all are critical
for an efficient antiviral immune response (Hoare et al.,
2006; Walters et al., 2018).
Our docking study confirmed the proper interaction of
fusMA of SARS-CoV-2 with HLA class I histocompatibility
antigen/beta-2-microglobulin that could result in a strong
and effective cell-mediated immunity (Figure 6A). MHC
II (HLA class II histocompatibility antigen) binds peptides
derived from antigens that access the endocytic route
of antigen-presenting cells (APC) and presents them
on the cell surface for recognition by the CD4 T-cells.
The peptide binding cleft accommodates peptides of
10–30 residues. The presented peptides by MHC class
II molecules are generated mostly by degradation of
proteins that access the endocytic route, where they are
processed by lysosomal proteases and other hydrolases.
Exogenous antigens that have been endocytosed by the
APC are thus readily available for presentation via MHC
II molecules, and for this reason, this antigen presentation
pathway is usually referred to as exogenous (Lenormand
et al., 2012). Our docking study clarified and confirmed
the interaction of fusMA with both HLA class I and
class II histocompatibility antigen heterodimers (Figure
6). According to our obtained data, fusMA of SARSCoV-2 showed a greater affinity for HLA class II that is
responsible for humoral immunity that is the major key
in the vaccination process (Figure 6). Furthermore, we
confirmed the interaction of fusMA of SARS-CoV-2
with TLR3 and TLR 4 that are vital for a potent immune
response against such kinds of viruses. TLRs (Toll-like

receptors) are a key component of innate and adaptive
immunity that control host immune response against
pathogens through recognition of molecular patterns
that are specific to microorganisms (Brikos and O’Neill,
2008). TLR3 is a nucleotide-sensing TLR that is activated
by double-stranded RNA as a sign of viral infection.
TLR3 acts via the adapter TRIF/TICAM1, leading to NFkappa-B activation, IRF3 nuclear translocation, cytokine
secretion, and the inflammatory response (de Bouteiller et
al., 2005; Johnsen et al., 2006). Toll-like receptor 4 (TLR4)
cooperates with LY96 and CD14 to mediate the innate
immune response to bacterial lipopolysaccharide (LPS)
(Tatematsu et al., 2016) and also acts via MYD88, TIRAP,
and TRAF6, leading to NF-kappa-B activation, cytokine
secretion, and the inflammatory response (Medzhitov et
al., 1997; Arbour et al., 2000; Tatematsu et al., 2016).
5. Conclusion
New problems could be solved by new kinds of solutions.
Today, all aspects of the human modern lifestyle are
influenced by the COVID-19 global pandemic, and
production of an efficient vaccine or introduction of an
effective medical treatment is an urgent requirement.
Although, the older generation of vaccines has abundant
advantages but is not so efficient against RNA viruses
with a high potential of mutation within their genome
that make them stronger with new epitopes (Stobart and
Moore, 2014). New technologies could open a novel vista
to design a pioneer generation of vaccines and medication.
DNA vaccines have lots of advantages such as simple and
economical preparation, immediate abundant production,
and the ability to express multiple epitopes that could
be very important for pathogens with high mutation
potential like RNA viruses (Liu, 2003). Here, we designed
a multiepitope DNA vaccine that expresses various
epitopes of nucleocapsid protein, membrane glycoprotein,
and ORF8 protein of SARS-CoV-2 and interleukin-2 and
beta-defensin 1 preproprotein as an adjuvant. Based on
our computational and predictional studies, the expressed
protein by this DNA vaccine (fuspMA) is a stable protein
with high and acceptable immunogenicity and tolerable
allergenicity and toxicity. We assume this strategy for
vaccine development can reduce the time and costs of
achieving an efficient vaccine against SARS-CoV-2 in
comparison to traditional methods. In the end, further
experimental in vivo condition is required to assess the
capability of the designed DNA vaccine and to evaluate its
competency for induction of appropriate and permanent
immunity against SARS-CoV-2.
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Supplementary 1. The final sequence of the designed chimeric vaccine against SARS-CoV-2 was consisted of a Kozak consensus
sequence, tissue plasminogen activator (TPA) signal peptide, TEV protease cleavage site and the vaccine sequence.
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